Development of 3D-Bioprinted Colitis-Mimicking Model to Assess Epithelial Barrier Function Using Albumin Nano-Encapsulated Anti-Inflammatory Drugs.

Autor: Almutary AG; Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia., Alnuqaydan AM; Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia., Almatroodi SA; Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia., Bakshi HA; The Hormel institute, Medical research Center, University of Minnesota, Austin, MN 55912, USA., Chellappan DK; Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia., Tambuwala MM; Lincoln Medical School, University of Lincoln, Brayford Pool Campus, Lincoln LN6 7TS, UK.
Jazyk: angličtina
Zdroj: Biomimetics (Basel, Switzerland) [Biomimetics (Basel)] 2023 Jan 18; Vol. 8 (1). Date of Electronic Publication: 2023 Jan 18.
DOI: 10.3390/biomimetics8010041
Abstrakt: Physiological barrier function is very difficult to replicate in vitro. This situation leads to poor prediction of candidate drugs in the drug development process due to the lack of preclinical modelling for intestinal function. By using 3D bioprinting, we generated a colitis-like condition model that can evaluate the barrier function of albumin nanoencapsulated anti-inflammatory drugs. Histological characterization demonstrated the manifestation of the disease in 3D-bioprinted Caco-2 and HT-29 constructs. A comparison of proliferation rates in 2D monolayer and 3D-bioprinted models was also carried out. This model is compatible with currently available preclinical assays and can be implemented as an effective tool for efficacy and toxicity prediction in drug development.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje